% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Kersting:285126,
      author       = {D. Kersting$^*$ and I.-A. Mavroeidi$^*$ and S. Settelmeier
                      and R. Seifert$^*$ and M. Schuler$^*$ and K. Herrmann$^*$
                      and T. Rassaf and C. Rischpler$^*$},
      title        = {{M}olecular {I}maging {B}iomarkers in {C}ardiooncology: {A}
                      {V}iew on {E}stablished {T}echnologies and {F}uture
                      {P}erspectives.},
      journal      = {Journal of nuclear medicine},
      volume       = {64},
      number       = {Suppl 2},
      issn         = {0097-9058},
      address      = {New York, NY},
      publisher    = {Soc.},
      reportid     = {DKFZ-2023-02250},
      pages        = {29S - 38S},
      year         = {2023},
      abstract     = {Novel therapeutic options have significantly improved
                      survival and long-term outcomes in many cancer entities.
                      Unfortunately, this improvement in outcome is often
                      accompanied by new and increasingly relevant therapy-related
                      cardiovascular toxicity. In this context, cardiooncology has
                      emerged as a new field of interdisciplinary individual
                      patient care. Important tasks are pretherapeutic risk
                      stratification and early detection and treatment of
                      cardiotoxicity, which comprises cardiac damage in relation
                      to cardiovascular comorbidities, the tumor disease, and
                      cancer treatment. Clinical manifestations can cover a broad
                      spectrum, ranging from subtle and usually asymptomatic
                      abnormalities to serious acute or chronic complications.
                      Typical manifestations include acute and chronic heart
                      failure, myo- and pericarditis, arrythmias, ischemia, and
                      endothelial damage. They can be related to almost all
                      current cancer treatments, including cytotoxic chemotherapy,
                      targeted therapy, immunotherapy, hormonal therapy, and
                      radiotherapy. Molecular imaging biomarkers can aid in
                      pretherapeutic cardiooncologic assessment for primary
                      prevention and personalized surveillance, detection, and
                      differential diagnosis of cardiotoxic complications.
                      Potential advantages over conventional diagnostics are the
                      higher detection sensitivity for subtle changes in cardiac
                      homeostasis, higher reproducibility, and better observer
                      independence. Hybrid imaging with highly sensitive PET/MRI
                      may be particularly suited for early diagnosis. Important
                      technologies that are encouraged in current
                      multidisciplinary guidelines are equilibrium radionuclide
                      angiography for evaluation of ventricular function and
                      chamber morphology, as well as myocardial perfusion imaging
                      for additional detection of ischemia. Novel modalities that
                      may detect even earlier signs of cardiotoxicity comprise
                      123I-metaiodobenzylguanidine SPECT to visualize sympathetic
                      innervation, 18F-FDG and somatostatin receptor
                      (68Ga-DOTATOC/DOTATATE) PET to indicate a metabolic shift
                      and inflammation, and 68Ga-fibroblast activation protein
                      inhibitor PET to monitor cardiac remodeling. In addition,
                      PET imaging of mitochondrial function has recently been
                      introduced in preclinical models and will potentially
                      broaden the field of application through higher sensitivity
                      and specificity and by enabling higher individualization of
                      diagnostic concepts.},
      keywords     = {cardiooncology (Other) / cardiotoxicity (Other) / molecular
                      imaging (Other) / nuclear cardiology (Other)},
      cin          = {ED01},
      ddc          = {610},
      cid          = {I:(DE-He78)ED01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:37918843},
      doi          = {10.2967/jnumed.122.264868},
      url          = {https://inrepo02.dkfz.de/record/285126},
}